Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹3,917 Cr
verified against source
Revenue YoY
4%
reported change
EBITDA
₹964 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Biocon's Q4 FY24 group revenue from operations grew 4% YoY to INR 3,917 crore, with core EBITDA margin of 30%. Biosimilars revenue grew 12% YoY, driven by strong U.S. market share gains (Fulphila 21%, Ogivri 18%, Semglee 15%) and record emerging markets sales. Generics revenue declined 3% YoY due to API pricing pressure, but formulations grew 36% YoY. Syngene revenue fell 8% YoY due to research funding slowdown. Management expects FY25 to be a year of consolidation with back-ended growth, driven by new product launches in generics (liraglutide) and biosimilars (ustekinumab, aflibercept). Key risks include delayed U.S. adalimumab market opening, FDA inspection outcomes for Bengaluru and Malaysia facilities, and sustained API pricing headwinds.
Colored figures show movement against the previous available record.
Guidance to track
- Syngene expects constant currency revenue growth of single-digit to low double-digit in FY25.
- Syngene expects operating EBITDA margin to be similar to FY24 levels (~31%).
- Biocon Biologics expects R&D investments to be in the 8%-9% of revenues range.
- Generics performance expected to build throughout the year with stronger second half, driven by new formulation launches.
Risks flagged
- Biosimilar adalimumab market in the U.S. is not expected to materially open until calendar 2025, delaying revenue contribution.
- Approvals for biosimilar bevacizumab and insulin aspart depend on FDA inspections of Bengaluru and Malaysia sites, which are pending.
- Generics API business continues to face pricing and demand challenges, impacting overall segment growth.
- Management declined to provide specific quantitative guidance on debt reduction, raising concerns about pace and magnitude.
Key quotes
- We were very pleased with our recent landmark success in our peptide portfolio through securing approval for liraglutide, a GLP-1 receptor agonist prescribed for diabetes as well as obesity in the U.K.
- We see GLPs as the major growth driver of the business from fiscal 26 onwards.
- We have signed a settlement and license agreement with Janssen Biotech and Johnson & Johnson, that clears the way to commercialize the product, in the U.S., subject to regulatory approval, no later than February 22, 2025.
Research modules